Since late 2022, the share of infections caused by the SARS-CoV-2 lineage XBB.1.5 has gradually increased in the United States, resulting in XBB.1.5 becoming the dominating SARS-CoV-2 lineage in the United States and a similar trend is likely to soon take place also in European countries. However, information on the virological properties of XBB.1.5 is scarce. Here, we conducted an initial virological assessment of the SARS-CoV-2 XBB.1.5 lineage.
No takes yet. Share an insight, caveat, or question.
Hoffmann et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: